1. Opening Hook
When pharma stocks promise “steady growth,” investors expect boring consistency.
Aarti Pharmalabs instead delivered growth with a side of margin pain, forex drama, and a ₹450 crore plant warming up but not yet paying rent.
Revenue moved up politely, EBITDA sulked like a teenager, and PAT took a hit—thanks to forex losses and the reality of second-year generic pricing. Meanwhile, CDMO kept humming in the background, Xanthine quietly stabilized, and API reminded everyone why timing matters in pharma launches.
Management didn’t sugarcoat the pain. They blamed fungible plants, CDMO prioritisation, inventory correction, and currency swings—basically everything except astrology.
If you’re here only for Q2 numbers, you’ll be disappointed.
If you’re here for FY27 and beyond, things get interesting.
Read on. The real molecule is still under development.
2. At a Glance
- Revenue ₹417 Cr (+11% YoY): Growth arrived, margins didn’t RSVP.
- EBITDA ₹75 Cr (–12% YoY): CDMO ate capacity, API ate margins.
- PAT ₹31 Cr (–35% YoY): Forex losses did their thing.
- Forex loss ₹7.4 Cr: Rupee depreciation reminded everyone who’s boss.
- CDMO +30–40% growth (guidance exceeded): Quietly becoming the adult in the room.
- Xanthine stable & growing: Boring, reliable, underappreciated.
3. Management’s Key Commentary
“CDMO projects were prioritised over intermediates.”
(Translation: We chose future money over current optics.) 😏
“Second year of generic launches always sees margin pressure.”
(Translation: Don’t extrapolate last year’s party.)
“EBITDA percentage is not something we track closely.”
(Translation: Stop obsessing over margins quarter by quarter.)
“Atali will be fully meaningful from FY27.”
(Translation: Patience is not optional.)
“We will exceed CDMO growth guidance.”
(Translation: This part actually deserves your attention.)
“API growth will normalize in H2.”
(Translation: Inventory correction, not structural decay.)
4. Numbers Decoded
Metric Q2 FY26 YoY Change
----------------------------------------------------
Revenue (₹ Cr) 417 +11%
EBITDA (₹ Cr) 75 -12%
EBITDA Margin ~18% Down
PAT (₹ Cr) 31 -35%
Forex Impact
